MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the imminent (February 20, 2008) release of its ProteoTuner systems, which will be featured in the April issue of Clontechniques, the company's quarterly newsletter. Based on work by researchers at Stanford University and licensed from Stanford, the ProteoTuner systems use a unique technology to regulate the amount of protein of interest present in a cell, quickly and directly. This new technique enables direct manipulation of the in vivo level of a specific protein of interest, making it a powerful tool for analyzing protein function. Because the system has very low toxicity, it is also suitable for animal studies.
"As a long-standing leader in the field of gene expression control, Clontech is proud to add the ProteoTuner systems to its extensive collection of gene and protein control systems, which include the Tet-On(R) Advanced and Tet-Off(R) Advanced Inducible Gene Expression systems for gene expression control and the Knockout(TM) RNAi systems for mRNA knockdown. Each of these three systems has particular, complementary strengths: the tight regulation of the Tet systems, Knockout RNAi's excellent control of endogenous protein levels, and the fast control of protein levels via the ProteoTuner systems. Each can be used independently or combined to enable exquisite control over protein expression," said Carol Lou, General Manager of Clontech Laboratories, Inc.
Clontech's ProteoTuner systems have broad applications in basic and applied research. The fast kinetics of protein stabilization/destabilization make it possible to study transient effects of the protein of interest that might otherwise have been masked. The ability to directly control the level of functional protein also makes this technology an unprecedented tool for dissecting the roles of multifunctional proteins, by directly and specifically "tuning" the level of a protein of interest in the cell. Thus, the ProteoTuner systems offer a unique new resource: the ability to directly regulate protein levels without affecting the normal translational and transcriptional activities of the gene of interest.
About Clontech Laboratories, Inc.
Clontech Laboratories, Inc. develops, produces, and markets leading-edge biological products to the life science market worldwide. Clontech has approximately 2,000 products that enable life science researchers to study genes, their products, and their cellular function through the use of innovative and powerful tools for gene cloning, labeling, and expression; as well as for elucidating protein:protein interactions; isolating and purifying DNA and proteins; and conducting a wide variety of PCR experiments. Clontech is a wholly-owned subsidiary of Takara Bio Inc. For more information visit http://www.clontech.com
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com
CONTACT: Andrew Farmer, Ph.D., Director, Business Development of Clontech
Laboratories, Inc., +1-650-919-7347, fax, +1-650-493-5569,
Web site: http://www.clontech.com/